全球精准心臟病学市场：趋势与成长机会

Global Precision Cardiology Market: Trends and Growth Opportunities

出版日期: 2026年02月17日 | 出版商:

Frost & Sullivan | 英文 57 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

跨行业合作以及尖端数位工具和技术的应用正在推动市场成长。

心血管疾病（CVD）仍然是全球发病和死亡的主要原因之一，自1990年以来，报告病例数翻了一番。目前，心血管疾病占全球所有死亡人数的三分之一，占全球所有死亡人数的32%，其中约85%是由心肌梗塞和缺血性中风引起的。这种成长趋势与人口老化以及高血压、肥胖和糖尿病等文明病因子的流行密切相关。其经济影响巨大；预计到2050年，美国与心血管疾病相关的年度医疗保健费用将达到1.49兆美元，而欧盟的总费用在2024年已超过3,261亿美元。

基因编辑技术、生物标记发现、数位生物标记和数位健康平台的进步正在加速向精准心臟病学的转型，从而实现更个人化和预测性的患者管理。 Avidity Biosciences 和 Verve Therapeutics 等生物製药创新公司正在开发下一代基于 RNA 和基因标靶治疗，而包括 Apple、Fitbit 和 Garmin 等公司穿戴式装置在内的消费者健康技术则支持对生理参数的持续监测。人工智慧 (AI) 和先进数据分析的整合将进一步增强心血管代谢疾病的早期检测、个人化监测、风险预测和疾病管理。数位双胞胎等数位技术正在改变诊断准确性和预后建模，使临床医生能够模拟治疗路径并提供个人化介入。基于机制的建模和多尺度模拟的日益普及凸显了它们在製定最佳治疗策略和推进精准心臟病学方面的重要作用。

在临床诊疗的连续过程中，医疗服务提供者致力于在降低治疗成本的同时改善治疗效果，因此，专注于优化药物剂量、减轻药物负担和管理突发风险的解决方案正日益受到关注。随着数位化和精准医疗干预措施的报销框架逐步扩展，用于治疗监测的预测分析正被临床医生、患者和保险公司更广泛地接受。

为了加强实证医学证据的累积并促进公平获取，製药公司正与学术机构、专业协会、政府机构和保险公司建立策略伙伴关係。这些合作旨在将专家小组纳入行业决策流程，并建立标准化、全面的诊疗路径。与美国心臟协会 (AHA) 和美国心臟病学会 (ACC) 等机构的合作，使安进和诺和诺德等公司能够推进政策支持、调整报销方案，并促进精准心臟病解决方案的更广泛应用。

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is strongly associated with population aging and an increasing prevalence of lifestyle-related risk factors, including hypertension, obesity, and diabetes. Economically, the impact is profound-annual CVD-related healthcare expenditures in the United States are projected to reach $1.49 trillion by 2050, while costs across the European Union have already exceeded $326.1 billion (2024).

Advancements in gene editing, biomarker discovery, digital biomarkers, and digital health platforms are accelerating the shift toward precision cardiology, enabling more personalized and predictive patient management. Biopharmaceutical innovators such as Avidity Biosciences and Verve Therapeutics are developing next-generation RNA-based and gene-targeted therapies, while consumer health technologies-including wearables from Apple, Fitbit, and Garmin-support continuous monitoring of physiological parameters. The integration of AI and advanced data analytics further enhances early detection, personalized monitoring, risk prediction, and disease management for cardiometabolic conditions. Digital technologies such as digital twins are transforming diagnostic accuracy and prognostic modeling, allowing clinicians to simulate treatment pathways and deliver tailored interventions. The increasing adoption of mechanistic modeling and multiscale simulations is helping define optimal therapeutic strategies, underscoring their role in propelling precision cardiology.

Within the clinical care continuum, solutions focused on dose optimization, reduced medication burden, and episodic risk management are gaining traction as healthcare providers seek to improve outcomes while minimizing treatment costs. Predictive analytics for treatment monitoring is gaining wider acceptance among clinicians, patients, and payers, supported by the gradual expansion of reimbursement frameworks for digital and precision-based interventions.

To strengthen evidence generation and promote equitable access, pharmaceutical companies are forming strategic partnerships with academic institutions, professional societies, government bodies, and payer organizations. These collaborations aim to integrate expert panels into industry decision-making processes and establish standardized, inclusive care pathways. Partnerships with agencies such as the American Heart Association (AHA) and the American College of Cardiology (ACC) have enabled companies, including Amgen and Novo Nordisk, to advance policy support, reimbursement alignment, and broader adoption of precision cardiology solutions.

Research Scope

Scope of Analysis
Segmentation

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8TM
The Impact of the Top 3 Strategic Imperatives on the Precision Cardiology Industry

Growth Opportunity Analysis

CVD Landscape
CVD Prevalence and Mortality
CVD Core Unmet Needs
Precision Health Application/Value Proposition across the Cardiology Care Continuum
Growth Drivers
Growth Restraints
Key Trends
Vendor Ecosystem

Growth Opportunity Analysis-Use Cases

Investment Trends
New Product Launches/Partnerships/Investor Funding

Growth Opportunity Analysis-Use Cases

CVD Diagnostics: Precision Diagnostics Testing and Monitoring Solutions
CVD Diagnostics: Key Challenges
Industry Use Case: Cardio Diagnostics
Industry Use Case: Ultromics

Growth Opportunity Analysis-Use Cases

Precision Cardiology: Treatment Ecosystem
CVDs: Treatment Approaches
Treatment (Therapeutics/Interventional/Non-Interventional Procedures)
CVDs: Personalized Therapies, Pipeline
Industry Use Case: Avidity Biosciences
Industry Use Case: Tenaya Therapeutics

Growth Opportunity Analysis-Use Cases

Monitoring/Surveillance: Devices and Patient Support Programs
CVDs: Monitoring/Surveillance: Devices and Patient Support Programs
Industry Use Case: Astellas Pharma, DIGITIVA
Industry Use Case: Cardiosense, CardioTag

Growth Opportunity Universe

Growth Opportunity 1: Improving CVD Care Pathways Across Emerging Countries through PPPs
Growth Opportunity 2: Biomarker-guided Precision Diagnostics for CVD
Growth Opportunity 3: Advanced Therapy Medicinal Products (ATMPs) for Rare Cardiovascular Diseases